	US 12,186,452 B2
	Compositions and methods useful in regenerative medicine
Themis Kyriakides, Branford, CT (US); and Aaron Morris, Ann Arbor, MI (US)
Assigned to Yale University, New Haven, CT (US)
Appl. No. 16/757,811
Filed by YALE UNIVERSITY, New Haven, CT (US)
PCT Filed Oct. 19, 2018, PCT No. PCT/US2018/056710 § 371(c)(1), (2) Date Apr. 21, 2020, PCT Pub. No. WO2019/083842, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/575,595, filed on Oct. 23, 2017.
Prior Publication US 2021/0308327 A1, Oct. 7, 2021
Int. Cl. A61L 27/36 (2006.01); A61K 9/06 (2006.01); A61K 35/28 (2015.01); A61K 35/32 (2015.01); A61K 35/33 (2015.01); A61K 35/34 (2015.01); A61K 35/545 (2015.01); A61K 45/06 (2006.01); A61L 27/52 (2006.01); A61L 27/54 (2006.01); A61P 17/02 (2006.01)

CPC A61L 27/3633 (2013.01) [A61K 9/06 (2013.01); A61K 35/28 (2013.01); A61K 35/32 (2013.01); A61K 35/33 (2013.01); A61K 35/34 (2013.01); A61K 35/545 (2013.01); A61K 45/06 (2013.01); A61L 27/52 (2013.01); A61L 27/54 (2013.01); A61P 17/02 (2018.01)]

9 Claims

1. A composition comprising a decellularized extracellular matrix (ECM) lacking thrombospondin-2 (TSP-2-null ECM) and a decellularized wild-type ECM produced by a wildtype cell that expresses TSP-2, wherein the TSP-2-null ECM is produced by a cell comprising a knock-out of the TSP-2 gene, wherein the cell comprising the knock-out of the TSP-2 gene does not express TSP-2, wherein a storage modulus of the composition is increased and decreased compared to the decellularized TSP-2-null ECM and the wildtype decellularized ECM, respectively.